NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
At risk: Primary completion moved at least 7 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 34 versions: 26 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Apr 10, 2027 to Nov 16, 2027 Show 6 more changesShow less
- Eligibility criteria expanded, about 18 words
- Enrollment closed, study ongoing
- Final enrollment: 100 participants (planned 87)
- Study completion pushed from Mar 9, 2028 to Oct 15, 2028
- Secondary endpoints: details revised at 3 of 14 entries
- Site details revised at 43 of 43 sites
- Minor Site details revised at 4 of 43 sitesv33
- Minor Site details revised at 7 of 43 sitesv32
- Minor Trial sites expanded: 21 → 43 locationsv31
- Minor Trial sites reduced: 43 → 21 locationsv30
Show 20 earlier versionsHide 20 earlier versions
- Minor Study sites: 38 to 43v28
- Minor Study sites: 37 to 38v26
- Minor Study sites: 35 to 37v24
- Study Status, Contacts/Locationsv23
- Study Status, Contacts/Locationsv22
- Minor Study sites: 34 to 35v20
- Minor Study sites: 31 to 34v18
- Minor Study sites: 30 to 31v17
- Minor Site details revised at 6 of 30 sitesv16
- Minor Study sites: 25 to 30
- Primary completion date: Mar 30, 2027 to Apr 10, 2027
- Study completion date: Feb 27, 2028 to Mar 9, 2028
- Minor Primary completion date: Jun 8, 2027 to Mar 30, 2027
- Study completion date: May 7, 2028 to Feb 27, 2028
- Minor Study sites: 23 to 25
- Primary completion date: Jul 2, 2027 to Jun 8, 2027
- Study completion date: May 31, 2028 to May 7, 2028
- Minor Study sites: 22 to 23
- Primary completion date: Jun 3, 2027 to Jul 2, 2027
- Study completion date: May 2, 2028 to May 31, 2028
- Minor Site details revised at 9 of 22 sitesv11
- Minor Enrollment target: 100 to 87
- Study sites: 17 to 22
- Primary completion date: Aug 28, 2027 to Jun 3, 2027
- Study completion date: Jul 27, 2028 to May 2, 2028
- Minor Study sites: 13 to 17
- Primary completion date: Aug 6, 2027 to Aug 28, 2027
- Study completion date: Jul 5, 2028 to Jul 27, 2028
- Minor Study sites: 10 to 13
- Primary completion date: Apr 10, 2027 to Aug 6, 2027
- Study completion date: Mar 9, 2028 to Jul 5, 2028
- Minor Study sites: 8 to 10v7
- Minor Study sites: 1 to 8v4
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary completion date: Aug 13, 2026 to Apr 10, 2027
- Study sites: 0 to 1
- Study completion date: Jun 17, 2028 to Mar 9, 2028
- Start date changed from estimate of Feb 3, 2024 to Feb 20, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part 1: Number of participants with dose limiting toxicity (DLT)
Timeframe: Cycle 1, about 28 days
Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Timeframe: Assessed from baseline up to 90 days after last dose of study treatment
Secondary (14)
Part 1: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Part 1 and Part 2: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity
Part 1 and Part 2: Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities
Part 1 and Part 2: Percentage of Participants with Objective Response Rate (ORR)
Part 1 and Part 2: Percentage of Participants with Complete Response Rate (CRR)
Show 9 moreShow less
Part 1 and Part 2: Time to Response (TTR)
Part 1 and Part 2: Duration of Response (DOR)
Part 1 and Part 2: Duration of Complete Response (DOCR)
Part 1 and Part 2: Time of Progression Free Survival (PFS)
Part 1 and Part 2: Time of Overall Survival (OS)
Part 1 and Part 2: Minimal Residual Disease (MRD) Negativity Rate
Part 1 and Part 2: Concentrations of elranatamab
Part 1 and Part 2: Concentrations of iberdomide
Part 1 and Part 2: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab
Arms and interventions
Part 1 Dose EscalationExperimental
Non-randomized elranatamab plus iberdomide
Part 2 Dose RandomizationExperimental
Randomized elranatamab plus iberdomide
Drugs: Elranatamab, Iberdomide
Sites
43 sites in 3 countries
United States 34, Australia 6, Canada 3